Table 3.
SARS-CoV-2 antibody positivity and reported COVID-19 exposures in persons who inject drugs and their partners, living with and without HIV (N = 1000)
| Characteristic | All (N = 1000) |
SARS-CoV-2 seropositive (N = 309) |
|---|---|---|
| n (%) | ||
| COVID-19 Symptoms in Past 2 Weeks* | ||
| Fever or chills | 231 (23.1) | 65 (21.0) |
| Cough | 305 (30.5) | 90 (29.1) |
| Shortness of breath or difficulty breathing | 92 (9.2) | 25 (8.1) |
| Muscle or body aches | 179 (17.9) | 46 (14.9) |
| Headache | 250 (25.0) | 79 (25.6) |
| New loss of taste or smell | 56 (5.6) | 17 (5.5) |
| Sore throat | 88 (8.8) | 20 (6.5) |
| Congestion or runny nose | 261 (26.1%) | 76 (24.6) |
| Nausea or vomiting | 111 (11.1) | 26 (8.4) |
| None | 390 (39.0) | 122 (39.5) |
| High-Risk Exposure in Past 2 Weeks | ||
| Yes | 29 (2.9) | 9 (2.9) |
| No | 971 (97.1) | 300 (97.1) |
| Any Sexual or Injecting Partners Diagnosed with COVID-19 | ||
| Yes | 32 (3.2) | 15 (4.9) |
| No | 968 (96.8) | 294 (95.1) |
| Any Sexual or Injecting Partners Died From COVID-19 or Flu-Like Illness since March 2020 | ||
| Yes | 44 (4.4) | 15 (4.9) |
| No | 956 (95.6) | 294 (95.1) |
| Any Housing Partners Diagnosed with COVID-19 | ||
| Yes | 34 (3.4) | 8 (2.6) |
| No | 966 (96.6) | 301 (97.4) |
| Any Housing Partners Died From COVID-19 or Flu-Like Illness since March 2020 | ||
| Yes | 30 (3.0) | 7 (2.3) |
| No | 969 (96.9) | 301 (97.4) |
*Participants with multiple symptoms are represented more than once